

Biologics and Genetic Therapies Directorate

Drug Submission Performance Annual Report

Fiscal Year

2018-2019

April 1 2018 – March 31 2019





Health Canada is the federal department responsible for helping the people of Canada maintain and improve their health. We assess the safety of drugs and many consumer products, help improve the safety of food, and provide information to Canadians to help them make healthy decisions. We work with the provinces to ensure our health care system serves the needs of Canadians.

Également disponible en français sous le titre : Direction des produits biologiques et des thérapies génétiques – Rapport annuel du rendement des présentations de drogue – Exercice financier 2018-2019

To obtain additional information, please contact:

Health Canada Address Locator 0202A1 101 Tunney's Pasture Driveway, Tunney's Pasture Ottawa, Ontario K1A 0K9 Tel.: 613-941-7281 Fax: 613-941-0825 E-mail: <u>hc.tpd.web.publications.sc@canada.ca</u>

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health, 2019

Publication date: June 2019

This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged.

Cat H166-4E-PDF ISSN 2561-763X Pub 190065

Table of Contents

TABLE OF CONTENTS	3
OVERVIEW	8
ACRONYMS	10
Submission Types	10
Documents	
FEE CATEGORIES	11
NDS & SNDS	12
SUBMISSIONS RECEIVED	13
New Drug Submissions (NDS) Received by Fee Category	13
Supplemental New Drug Submissions (SNDS) Received by Fee Category	13
WORKLOAD	14
New Drug Submission (NDS) Review Workload / Backlog	14
Supplemental New Drug Submission (SNDS) Review Workload / Backlog	14
New Drug Submission (NDS) Review Workload by Fee Category	15
Supplemental New Drug Submission (SNDS) Review Workload by Fee Category	15
APPROVALS	16
New Drug Submission (NDS) Approvals by Fee Category and by NOC Type	16
NDS Approval Times	16
Supplemental New Drug Submission (SNDS) Approvals by Fee Category and by NOC Type	17
SNDS Approval Times	17
NEW ACTIVE SUBSTANCE and PRIORITY APPROVAL LISTS	
New Active Substance Approvals (NAS) – BGTD - Fiscal Year 2018-2019	
Priority Submission Approvals – BGTD - Fiscal Year 2018-2019	20
Biosimilars: NDS & SNDS Market Authorizations	22
Biosimilars: Number of NDS & SNDS that were issued an NOC by Fiscal Year	22
Biosimilars: List of NDS & SNDS issued an NOC - Fiscal Year 2018-19	22
REVIEW CYCLE DECISIONS	24

New Drug Submission (NDS) Review Decisions	
NDS: Review Cycle Completions Showing Percentage Within Target	
Supplemental New Drug Submission (SNDS) Review Decisions	25
SNDS: Review Cycle Completions Showing Percentage Within Target	
SCREENING CYCLE DECISIONS	26
New Drug Submission (NDS) Screening Decisions	
NDS: Screening Cycle Completions Showing Percentage Within Target	
Supplemental New Drug Submission (SNDS) Screening Decisions	27
SNDS: Screening Cycle Completions Showing Percentage Within Target	
REQUESTS FOR RECONSIDERATION OF FINAL DECISIONS	28
Requests for Reconsideration of Final Decisions -NDS, SNDS & ANDS	
PRIORITY REVIEW STATUS REQUEST (FOR NDS & SNDS)	30
Priority Review Status Requests Received	30
Priority Review Status Requests: Decisions Rendered	30
Priority Review Status Requests: Performance	
REQUESTS FOR RECONSIDERATION OF FINAL DECISIONS	31
Requests for Reconsideration of Final Decisions – Priority Review Requests (for NDS and SNDS)	31
NOTIFIABLE CHANGES (NC)	32
Number Received - Notifiable Changes (NC)	33
WORKLOAD	34
Notifiable Change (NC) SAFETY: Review Workload / Backlog	
Notifiable Change (NC) QUALITY: Review Workload / Backlog	
Notifiable Change (NC) SAFETY: Review Workload by Class	35
Notifiable Change (NC) QUALITY: Review Workload by Class	35
PERFORMANCE	36
REVIEW Completions by Class - Notifiable Changes (NC)	
SCREENING Completions by Class - Notifiable Changes (NC)	
Decision Documents by Class - Notifiable Change (NC)	
REQUESTS FOR RECONSIDERATION OF FINAL DECISIONS	
Requests for Reconsideration of Final Decisions – Notifiable Changes (NC)	37
ADMINISTRATIVE SUBMISSIONS	38
ADMINISTRATIVE SUBMISSIONS (BGTD)	
BGTD Annual Drug Submission Performance Report: April 1 2018– March 3	

Administrative Submission Approvals (with BGTD Review)	.40 .40 .42 .42 .42 .42 .42 .43 .43
Administrative Submissions Received by Submission Type	.40 .40 42 .42 .42 .42 .42 43 .43
Administrative Submissions Received by Submission Type	.40 .40 42 .42 .42 .42 .42 43 .43
CLINICAL TRIAL APPLICATIONS Application (CTA) Number Received - Clinical Trial Application (CTA) Decision Documents - Clinical Trial Application (CTA) Performance - Clinical Trials Applications (CTA) Reviews Meeting the 30 Day Target Performance - Clinical Trials Applications (CTA) Number Received - Clinical Trial Application-Amendments (CTA-A) Application - Amendments (CTA-A) Decision Documents - Clinical Trial Application-Amendments (CTA-A) Application - Amendments (CTA-A) Decision Documents - Clinical Trial Application Amendments (CTA-A) Application - Amendments (CTA-A) Decision Documents - Clinical Trial Application Amendments (CTA-A) Application - Amendments (CTA-A) Decision Documents - Clinical Trial Application Amendments (CTA-A) Application - Amendments (CTA-A) Ding: Application For A DRUG IDENTIFICATION NUMBER – BIOLOGICAI Biological	42 .42 .42 .42 43 .43
 Number Received - Clinical Trial Application (CTA) Decision Documents - Clinical Trial Application (CTA) Performance - Clinical Trials Applications (CTA) Reviews Meeting the 30 Day Target CLINICAL TRIAL APPLICATION-AMENDMENTS Number Received - Clinical Trial Application-Amendments (CTA-A) Decision Documents - Clinical Trial Application-Amendments (CTA-A) Performance - Clinical Trial Application Amendments (CTA-A) 	.42 .42 .42 43 .43
Decision Documents - Clinical Trial Application (CTA) Performance - Clinical Trials Applications (CTA) Reviews Meeting the 30 Day Target CLINICAL TRIAL APPLICATION-AMENDMENTS Number Received - Clinical Trial Application-Amendments (CTA-A) Decision Documents - Clinical Trial Application-Amendments (CTA-A) Performance - Clinical Trial Application Amendments (CTA-A) Reviews DINB: APPLICATION FOR A DRUG IDENTIFICATION NUMBER – BIOLOGICAI	.42 .42 43 .43 .43
Performance - Clinical Trials Applications (CTA) Reviews Meeting the 30 Day Target	.42 43 .43 .43
CLINICAL TRIAL APPLICATION-AMENDMENTS	43 .43 .43
Number Received - Clinical Trial Application-Amendments (CTA-A) Decision Documents - Clinical Trial Application-Amendments (CTA-A) Performance - Clinical Trial Application Amendments (CTA-A) Reviews DINB: APPLICATION FOR A DRUG IDENTIFICATION NUMBER – BIOLOGICAL	.43 .43
Decision Documents - Clinical Trial Application-Amendments (CTA-A) Performance - Clinical Trial Application Amendments (CTA-A) Reviews DINB: APPLICATION FOR A DRUG IDENTIFICATION NUMBER – BIOLOGICAL	.43
Performance - Clinical Trial Application Amendments (CTA-A) Reviews DINB: APPLICATION FOR A DRUG IDENTIFICATION NUMBER – BIOLOGICAL	
DINB: APPLICATION FOR A DRUG IDENTIFICATION NUMBER – BIOLOGICAL	.43
DINB: Number Received	
WORKLOAD	16
DINB: Review Workload Showing Percentage in Backlog	
DINB: Review Workload biowing referinge in Dacking	
DINB: Screening Workload Showing Percentage in Backlog	
DINB: Screening Workload by Class	
DECISION DOCUMENTS	.48
DINB: Decision Documents by Class	.48
REQUESTS FOR RECONSIDERATION OF FINAL DECISIONS	.48
DINB: Requests for Reconsideration of Final Decisions	.48
PERFORMANCE	.49
DINB: Review Cycle Completions	.49
DINB: Screening Cycle Completions	.49
PDC-B: POST AUTHORIZATION DIVISION 1 CHANGES - BIOLOGICS	50
PDC-B: Post Authorization Division 1 Changes- Biologics Received	
YBPR: YEARLY BIOLOGIC PRODUCT REPORTS	.50

	Yearly Biologic Product Reports (YBPR) Received
52	APPENDIX A: PRE-SUBMISSION MEETINGS .
	Pre-submission Meetings Held / Feedback Provided

This page is left blank intentionally.

OVERVIEW

The Biologics and Genetic Therapies Directorate's (BGTD) Annual Drug Submission Performance Report reflects biologic and radiopharmaceutical drug submission review activity over five consecutive fiscal years (April 1 to March 31) from 2014-2015 to 2018-2019.

Statistics are provided by submission type and show the number received, the number in workload, the number of decisions, the number of approvals and approval times. The report lists details of Priority Submissions and New Active Substances approved during the fiscal year Apr 1 2018 to March 31 2019.

General Information

There are several steps involved in the drug submission review¹ and approval process:

- administrative processing,
- regulatory and scientific screening and
- in-depth scientific review.

When deficiencies or non-compliance issues are found, a company may submit responses before a final decision can be reached and thus multiple review cycles may be required. A submission's approval time can vary depending on the number and type of review cycles needed.

Submissions Received are counts of submissions received during the year using the filing date (CR date) which is the date the submission is considered administratively complete by Health Canada.

Workload is the number of submissions "under active review" on the last day of the quarter. **"Backlog"** is the proportion of the workload that is over target. Often the term workload is used to mean the amount of work received over a period of time and is a common source of confusion.

Approvals² are Notice of Compliances (NOC) Issued or Issuable. An NOC issuable is when a submission's NOC is placed "on hold" awaiting authorization to market, due to Patented Medicines (NOC) Regulations or due to changes from Prescription to Non-Prescription.

¹ For further clarification refer to the <u>Guidance for Industry: Management of Drug Submissions</u>.

² Final results from confirmatory trials submitted in the form of an SNDS-C are now included in the SNDS Received, Workload and Performance figures. SNDS-C are not included in the SNDS Approval figures. For further Clarification refer to the <u>Guidance Document:</u> Notice of Compliance with Conditions (NOC/c).

A **review cycle completion**³ is counted upon the conclusion of an in-depth scientific review that then results in a decision of approval or non-approval. The time taken is compared to a set <u>performance standard</u>⁴ which is based on the type of submission, class and cycle (status). For example, in the case of a Priority NDS, the performance standard is 180 days for Review1 and 90 days for Review2. Health Canada has set a goal of 90% of review cycle completions to be rendered within performance standards.

"First Cycle Review" Approvals are those submissions approved without having to go through several review cycles to resolve submission deficiencies or non-compliance issues, and exclude "refiled"⁵ submissions.

Any questions or comments on this report should be forwarded to:

Office of Submissions and Intellectual Property, Resource Management and Operations Directorate Finance Building, A.L. # 0202A1 101 Tunney's Pasture Driveway, Tunney's Pasture Ottawa, Ontario, K1A 0K9

Tel: (613) 941-7281 Fax: (613) 941-0825

Email: <u>hc.osip-bppi.sc@canada.ca</u>

BGTD Annual Drug Submission Performance Report:

³ Review cycles include all types e.g. Review 1, Review 2, Review QN. The total number of "review decisions" may surpass the total number of review cycle completions as they include cancellations/withdrawals that occur while the submission is 'inactive'. For example, a withdrawal can be issued when a company fails to respond to a notice of non-compliance within the allotted time frame. A 'Cancelled by Company' is counted as a review decision when a company sends a cancellation letter after the submission's original materials have been accepted for review.

⁴ Performance continues to be measured against performance standards for Submission Type/Submission Class/ Status combinations as set out in Appendix 3 of the <u>Guidance for Industry: Management of Drug Submissions</u>. This is not to be confused with the 'UF Review 1 (iteration 1)' performance standards that are employed to measure performance to meet the *User Fees Act* reporting Requirements in the 'Health Canada Departmental Performance Report (DPR).

⁵ For further clarification refer to the <u>Guidance for Industry: Management of Drug Submissions</u>

ACRONYMS

Submission Types

СТА	-	Clinical Trial Application
CTA-A	-	Clinical Trial Application-Amendment
DINB	-	Application for a DIN – Biological Product
NDS	-	New Drug Submission
NC	-	Notifiable Change – New Drug
PDC-B		Post-Authorization Division 1 Changes - Biologics
PRNDS	-	Request for Priority Review Status: New Drug Submission
PRSNDS	-	Request for Priority Review Status: Supplemental New Drug Submission
SNDS	-	Supplemental New Drug Submission
SNDS-C	-	Supplemental New Drug Submission – CONFIRMATORY
YBPR	-	Yearly Biologic Product Report
Documents		

NOC	-	Notice of Compliance		
NOC-c	-	Notice of Compliance with Conditions		
Issuable NOC (Patent)	-	NOC on Hold due to Patented Medicines (NOC) Regulations		
Issuable NOC (Rx to OTC) -		NOC on Hold due to changes (Prescription to Non-Prescription)		
NON	-	Notice of Non-Compliance		
NOD	-	Notice of Deficiency		
NON Withdrawal	-	Notice of Non-Compliance Withdrawal Letter		
NOD Withdrawal	-	Notice of Deficiency Withdrawal Letter		

Fee Categories

Fee Category	Fee Category Description
New Active Substance (NAS)	Submission in support of a drug, excluding a disinfectant, that contains a medicinal ingredient not previously approved in a drug for sale in Canada, and that is not a variation of a previously approved medicinal ingredient such as a salt, ester, enantiomer, solvate or polymorph. For biologics, this submission class does not include an NDS in support of a subsequent entry biologic or an SNDS in support of changes to the manufacturing process of biologics.
Clinical or Non-Clinical Data and Chemistry and Manufacturing data	Submissions based on clinical or non-clinical data and chemistry and manufacturing data for a drug that does not include a NAS.
Clinical or Non-Clinical Data Only	Submissions based only on clinical or non-clinical data for a drug that does not include a NAS.
Comparative Studies	Submissions based on comparative studies with or without chemistry and manufacturing data for a drug that does not include a NAS. It excludes superiority and non-inferiority studies since they are clinical studies. It also excludes pharmaceutical equivalence studies since they are captured by the chemistry and manufacturing fee.
Chemistry and Manufacturing Data Only	Submissions based only on chemistry and manufacturing data for a drug that does not include a NAS.
Published Data Only	Submissions based only on published clinical or non-clinical data for a drug that does not include a NAS.
Switch from Prescription to Nonprescription Status	Submissions based only on data that support the modification or removal of a medicinal ingredient on the <u>Prescription Drug List</u> . This fee is limited to switches from prescription to nonprescription status when an identical claim is made for an existing drug.
Labelling Only ⁶	Submissions of labelling material that do not include supporting clinical or non-clinical data or chemistry and manufacturing data.
Administrative Submission ⁷	Submissions in support of a manufacturer or product name change.
Disinfectants ⁸	Submissions and applications that include data in support of a disinfectant.
Drug Identification Number (DIN) - Labelling Standards	Applications attesting to compliance with a labelling standard or Category IV Monograph (DINF) for a drug that does not include clinical or non-clinical data or chemistry and manufacturing data.

For further information, please refer to the <u>Guidance Document - Fees for the Review of Drug</u> <u>Submissions and Applications</u>

BGTD Annual Drug Submission Performance Report:

⁶ For more information, please consult the <u>Guidance Document: Question and Answers about Plain Language Labelling</u>

⁷ For additional information, please consult the <u>"Changes in Manufacturer and/or Product Name Policy" (2015)</u>

⁸ The non-prescription (or over-the-counter) and disinfectant drug review functions were moved from TPD to the Natural and Non-prescription Health Products Directorate (NNHPD) on July 1, 2013. These products are reported on in a separate NNHPD Drug Submission Performance Report.

New Drug Submission (NDS)


&

Supplemental New Drug Submission (SNDS)


SUBMISSIONS RECEIVED



9 10



Supplemental New Drug Submissions (SNDS) Received by Fee Category




⁹ Submissions granted Priority Review Status or found eligible for advance NOC/c consideration are assigned a shortened review target to account for the Priority nature of the submission. For further clarification, please see the <u>Priority Review of Drug Submissions Policy</u>, the <u>Notice of Compliance with conditions (NOC/c) Guidance</u> and the <u>Management of Drug Submissions Guidance</u>.


¹⁰ **Biosimilar**: A biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug. Biosimilar relies in part on prior information regarding safety and efficacy that is deemed relevant due to the demonstration of similarity to the reference biologic drug and which influences the amount and type of original data required.

WORKLOAD

New Drug Submission (NDS) Review Workload / Backlog



Supplemental New Drug Submission (SNDS) Review Workload / Backlog



WORKLOAD


NDS All REVIEW WORKLOAD BY FEE CATEGORY - BGTD						
(excluding administrative) and Fiscal Year End						
2015-03-31 2016-03-31 2017-03-31 2018-03-31 2019-03						
Clinical or Non-Clin and C&M	8	11	11	21	10	
Backlog	0	0	0	0	0	
New Active Substance	12	10	14	9	10	
Backlog	0	0	0	0	0	
Total	20	21	25	30	20	
Non Backlog	20	21	25	30	20	
Backlog	0	0	0	0	0	
% in Backlog	0%	0%	0%	0%	0%	
Priority (subset)	2	1	1	5	0	
Backlog	0	0	0	0	0	

New Drug Submission (NDS) Review Workload by Fee Category


Supplemental New Drug Submission (SNDS) Review Workload by Fee Category

SNDS and SNDS-C All REVIEW WORKLOAD BY FEE CATEGORY - BGTD					
(excluding administrative) and Fiscal Year End					
	2015-03-31	2016-03-31	2017-03-31	2018-03-31	2019-03-31
Comparative Studies	3	0	1	1	4
Backlog	0	0	0	0	0
Chemistry & Manufacturing	32	25	28	26	26
Backlog	0	0	0	0	0
Clinical or Non-Clin Only	25	37	44	54	49
Backlog	0	0	0	0	0
Published Data	3	1	3	2	3
Backlog	0	0	0	0	0
Clinical or Non-Clin and C&M	5	10	4	4	6
Backlog	0	0	0	0	0
Labelling Only	0	1	5	7	10
Backlog	0	0	0	0	0
Total	68	74	85	94	98
Non Backlog	68	74	85	94	98
Backlog	0	0	0	0	0
% in Backlog	0%	0%	0%	0%	0%
Priority (subset)	0	2	3	2	4
Backlog	0	0	0	0	0
SNDS-C (Confirmatory)	2	3	3	5	5
Backlog	0	0	0	0	0

APPROVALS New Drug Submission (NDS) Approvals by Fee Category and by NOC Type



NDS Approval Times




Approval Time is the total number of calendar days between the date a submission is filed (CR date) and the date it is approved (NOC Issuable). This includes time in processing, screening, review and any time taken by the company to respond to notices of deficiency or non-compliance.

Biosimilar: A biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug. Biosimilar relies in part on prior information regarding safety and efficacy that is deemed relevant due to the demonstration of similarity to the reference biologic drug and which influences the amount and type of original data required.

Supplemental New Drug Submission (SNDS) Approvals by Fee Category and by NOC Type

				pprovals by F inistrative and SNDS-C	ee Category Confirmatory Studies)
	250					
ole	200				Total	Total 176
sual	200			Total	100	1/6
1/Is	150		Total 120	132	52	50
suec		Total	46	23	2	4
<u>8</u>	100	81	35	36	<mark>50</mark>	53
Ň N		⁹ 3 26	4 3	111	7 5	42
No. of NOC Issued / Issuable	50	4 1 38	68	59	64	63
	0 -	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019
Labelling Only		9	6	23	52	50
Comparative Studies		3	4	2	2	4
Clinical or Non-Clin O	nly	26	35	36	50	53
Published Data Only		1	3	1	5	2
Clinical or Non-Clin a	nd C&M	4	4	11	7	4
Chemistry & Manufa	cturing	38	68	59	64	63
Total		81	120	132	180	176
Notice of Compliance	9	81	120	127	175	174
NOC with Conditions		0	0	2	4	1
Priority (subset)		0	0	3	4	2
NOC-C Class		0	0	2	4	1
Biosimilar		0	3	6 *	6 *	9

SNDS Approval Times



Approval Time is the total number of calendar days between the date a submission is filed (CR date) and the date it is approved (NOC Issuable). This includes time in processing, screening, review and any time taken by the company to respond to notices of deficiency or non-compliance

Biosimilar: A biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug. Biosimilar relies in part on prior information regarding safety and efficacy that is deemed relevant due to the demonstration of similarity to the reference biologic drug and which influences the amount and type of original data required.

New Active Substance Approvals (NAS) – BGTD - Fiscal Year 2018-2019

New Active Substance Approvals (NAS) – BGTD Fiscal Year 2018-2019 (April 1 2018 to March 31 2019)					
Brand Name (Active Ingredient(s)) - Indication(s)	Class	Company	Filing (CR Date ¹¹)	Approval Date (dd-mon-yy)	
AIMOVIG (Erenumab) - is indicated for prevention of migraine in adults who have at least 4 migraine days per month.	NAS	Novartis Pharmaceuticals Canada Inc.	18-Aug-17	1-Aug-18	
BIOTHRAX (Anthrax Antigen Filtrate) - is indicated for active immunization for the prevention of disease caused by Bacillus anthracis, in individuals 18 through 65 years of age, whose occupation or other activities place them at risk of exposure, regardless of the route of exposure.	NAS	Emergent Biodefense Operations Lansing LLC	29-Dec-17	13-Dec-18	
BRINEURA (Cerliponase Alfa) - is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.	PRIORITY- NAS	Biomarin International Limited	25-May-18	19-Dec-18	
CRYSVITA (Burosumab) - is indicated for the treatment of X-linked hypophosphataemia (XLH) in adult and pediatric patients 1 year of age and older.	PRIORITY- NAS	Kyowa Kirin Limited	16-May-18	5-Dec-18	
HEMLIBRA (Emicizumab) - is indicated for hemophilia A (congenital factor VIII deficiency) patients with factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes.	PRIORITY- NAS	Hoffmann-La Roche Limited	9-Jan-18	2-Aug-18	
JIVI (Antihemophilic Factor (Recombinant, B-domain deleted, PEGylated)) - is indicated in previously treated adults and adolescents (≥12 years of age) with hemophilia A (congenital Factor VIII deficiency) for: • Routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes; • Control and prevention of episodic bleeding; • Perioperative management of bleeding (surgical prophylaxis).	NAS	Bayer Inc.	3-Nov-17	18-Oct-18	
KYMRIAH (Tisagenlecleucel) - is a CD19-directed genetically modified autologous T- cell immunocellular therapy indicated for: the treatment of pediatric and young adult patients 3 to 25 years with B-cell acute lymphoblastic leukemia (ALL) who are refractory, have relapsed after allogeneic stem cell transplant (SCT) or are otherwise ineligible for SCT, or have experienced second or later relapse.	PRIORITY- NAS	Novartis Pharmaceuticals Canada Inc.	9-Feb-18	5-Sep-18	

¹¹ The CR Date is the date the submission is received and considered administratively complete by Health Canada

New Active Substance Approvals (NAS) – BGTD Fiscal Year 2018-2019 (April 1 2018 to March 31 2019)

(April 1 2018 to March 31 2019)						
Brand Name (Active Ingredient(s)) - Indication(s)	Class	Company	Filing (CR Date ¹¹)	Approval Date (dd-mon-yy)		
LUTATHERA (Lutetium (177Lu) Oxodotreotide) - is indicated for the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor- positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults with progressive disease.	PRIORITY- NAS	Advanced Accelerator Applications USA, Inc.	18-Jun-18	9-Jan-19		
OXERVATE (Cenegermin) - is indicated for the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.	PRIORITY- NAS	Dompé Farmaceutici S.P.A.	16-Jul-18	8-Feb-19		
PANHEMATIN (Hemin) is indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate.	PRIORITY- NAS	Recordati Rare Diseases Canada Inc.	20-Dec-17	13-Jul-18		
TAKHZYRO (Lanadelumab) - is indicated for routine prevention of attacks of hereditary angioedema (HAE) in adolescents and adults.	PRIORITY- NAS	Shire Pharma Canada ULC	22-Feb-18	19-Sep-18		
UNITUXIN (Dinutuximab) - in combination with granulocyte-macrophage colony- stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13 cis-retinoic acid (RA), for the treatment of high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.	NAS	United Therapeutics Corporation	14-Dec-17	28-Nov-18		
VONVENDI (von Willebrand factor (Recombinant)) - is indicated for: • treatment and control of bleeding episodes in adults (age ≥18) diagnosed with von Willebrand Disease (VWD). • Perioperative management of bleeding in adults (age ≥18) diagnosed with VWD.	NAS	Shire Pharma Canada ULC	26-Jan-18	10-Jan-19		
YESCARTA (Axicabtagene Ciloleucel) - is a CD19-directed genetically modified autologous T cell immunotherapy indicated for: the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.	PRIORITY- NAS	Gilead Sciences Canada Inc.	23-Jul-18	13-Feb-19		

Priority Submission Approvals – BGTD - Fiscal Year 2018-2019

Priority Submission Approvals – BGTD Fiscal Year 2018-2019 (April 1 2018 to March 31 2019)								
Brand Name (Active Ingredient(s)) - Indication(s)	Class	Company	Filing (CR Date ¹²)	Approval Date (dd-mon- yy)				
BRINEURA (Cerliponase Alfa) - is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.	PRIORITY- NAS	Biomarin International Limited	25-May-18	19-Dec-18				
CRYSVITA (Burosumab) - is indicated for the treatment of X-linked hypophosphataemia (XLH) in adult and pediatric patients 1 year of age and older.	PRIORITY- NAS	Kyowa Kirin Limited	16-May-18	5-Dec-18				
HEMLIBRA (Emicizumab) - is indicated for hemophilia A (congenital factor VIII deficiency) patients with factor VIII inhibitors as routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes.	PRIORITY- NAS	Hoffmann-La Roche Limited	9-Jan-18	2-Aug-18				
KYMRIAH (Tisagenlecleucel) - is a CD19-directed genetically modified autologous T-cell immunocellular therapy indicated for: the treatment of pediatric and young adult patients 3 to 25 years with B-cell acute lymphoblastic leukemia (ALL) who are refractory, have relapsed after allogeneic stem cell transplant (SCT) or are otherwise ineligible for SCT, or have experienced second or later relapse.	PRIORITY- NAS	Novartis Pharmaceuticals Canada Inc.	9-Feb-18	5-Sep-18				
KYMRIAH (Tisagenlecleucel) - is a CD19-directed genetically modified autologous T-cell immunocellular therapy indicated for: the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.	PRIORITY- CLIN/C&M	Novartis Pharmaceuticals Canada Inc.	14-Feb-18	5-Sep-18				

 $^{^{\}rm 12}$ The CR Date is the date the submission is received and considered administratively complete by Health Canada

Priority Submission Approvals – BGTD Fiscal Year 2018-2019 (April 1 2018 to March 31 2019)								
Brand Name (Active Ingredient(s)) - Indication(s)	Class	Company	Filing (CR Date ¹²)	Approval Date (dd-mon- yy)				
LUTATHERA (Lutetium (177Lu) Oxodotreotide) - is indicated for the treatment of unresectable or metastatic, well-differentiated, somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults with progressive disease.	PRIORITY- NAS	Advanced Accelerator Applications USA, Inc.	18-Jun-18	9-Jan-19				
OPDIVO (Nivolumab) - new indication: Metastatic Renal Cell Carcinoma (RCC): OPDIVO, in combination with ipilimumab, is indicated for the treatment of adult patients with intermediate/poor-risk advanced or metastatic RCC.	PRIORITY- CLIN ONLY	Bristol-Myers Squibb Canada	13-Dec-17	6-Jul-18				
OXERVATE (Cenegermin) - is indicated for the treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.	PRIORITY- NAS	Dompé Farmaceutici S.P.A.	16-Jul-18	8-Feb-19				
PANHEMATIN (Hemin) is indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate.	PRIORITY- NAS	Recordati Rare Diseases Canada Inc.	20-Dec-17	13-Jul-18				
SOLIRIS (Eculizumab) - new indication: is indicated in adult patients with generalized Myasthenia Gravis (gMG).	PRIORITY- CLIN ONLY	Alexion Pharma GMBH	25-Jan-18	20-Aug-18				
TAKHZYRO (Lanadelumab) - is indicated for routine prevention of attacks of hereditary angioedema (HAE) in adolescents and adults.	PRIORITY- NAS	Shire Pharma Canada ULC	22-Feb-18	19-Sep-18				
YESCARTA (Axicabtagene Ciloleucel) - is a CD19-directed genetically modified autologous T cell immunotherapy indicated for: the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.	PRIORITY- NAS	Gilead Sciences Canada Inc.	23-Jul-18	13-Feb-19				

Biosimilars: NDS & SNDS Market Authorizations

Biosimilars: Number of NDS & SNDS that were issued an NOC by Fiscal Year

	Fiscal Year of Market Authorization							
Subm Type	Class	2014-15	2015-16	2016-17	2017-18	2018-19		
NDS	CLIN/C&M	0	2	1	3	5		
NDS Total		0	2	1	3	5		
SNDS	C&M ONLY	0	1	2	1	3		
	C&M/LABELLING	0	0	1	0	0		
	CLIN ONLY	0	0	0	0	2		
	CLIN/C&M	0	0	2	0	0		
	COMP/C&M	0	0	1	0	1		
	LABELLING ONLY	0	1	0	4	2		
	PUBLISHED DATA ONLY	0	1	0	0	0		
SNDS Total		0	3	6	5	8		

Biosimilars: List of NDS & SNDS issued an NOC - Fiscal Year 2018-19


Subm Type	Brand Name	Class	Company Active		Quarter FY 2018-19	Notice of Compliance (NOC) Date		
NDS	FULPHILA	CLIN/C&M	BGP PHARMA ULC	PEGFILGRASTIM	Q3	2018-Dec-24		
	HADLIMA, HADLIMA PUSHTOUCH	CLIN/C&M	SAMSUNG BIOEPIS CO., LTD	ADALIMUMAB	Q1	2018-May-08		
	HADLIMA, HADLIMA PUSHTOUCH	CLIN/C&M	SAMSUNG BIOEPIS CO., LTD	ADALIMUMAB	Q1	2018-May-08		
	LAPELGA	CLIN/C&M	APOTEX INC.	PEGFILGRASTIM	Q1	2018-Apr-05		
	MVASI	CLIN/C&M	AMGEN CANADA INC	BEVACIZUMAB	Q1	2018-Apr-30		
New Dru	ig Submission Total					5		
SNDS	ADMELOG	LABELLING ONLY	SANOFI-AVENTIS CANADA INC	INSULIN LISPRO	Q1	2018-Apr-30		
	BASAGLAR	C&M ONLY	ELI LILLY CANADA INC	INSULIN GLARGINE	Q1	2018-May-10		
	BRENZYS	LABELLING ONLY	SAMSUNG BIOEPIS CO., LTD	ETANERCEPT	Q1	2018-Jun-18		
	BRENZYS (PFP), BRENZYS (PFS)	CLIN ONLY	SAMSUNG BIOEPIS CO., LTD	ETANERCEPT	Q1	2018-Jun-14		
	ERELZI	CLIN ONLY	SANDOZ CANADA INCORPORATED	ETANERCEPT	Q4	2019-Jan-17		
	ERELZI (SENSOREADY PEN), ERELZI (PREFILLED SYRINGE)	C&M ONLY	SANDOZ CANADA INCORPORATED	ETANERCEPT	Q4	2019-Feb-11		
	ERELZI (SYRINGE), ERELZI (PEN)	C&M ONLY	SANDOZ CANADA INCORPORATED	ETANERCEPT	Q4	2019-Feb-27		
	RENFLEXIS	COMP/C&M	SAMSUNG BIOEPIS CO., LTD	INFLIXIMAB	Q3	2018-Nov-06		
Supplen	Supplemental New Drug Submission Total							

Please note: Approved Biosimilars that remain on Intellectual Property HOLD are not included.

Biosimilar: A biologic drug that enters the market subsequent to a version previously authorized in Canada, and with demonstrated similarity to a reference biologic drug. Biosimilar relies in part on prior information regarding safety and efficacy that is deemed relevant due to the demonstration of similarity to the reference biologic drug and which influences the amount and type of original data required


This page is left blank intentionally.

REVIEW CYCLE DECISIONS




New Drug Submission (NDS) Review Decisions

NDS: Review Cycle Completions Showing Percentage Within Target




REVIEW CYCLE DECISIONS




Supplemental New Drug Submission (SNDS) Review Decisions

SNDS: Review Cycle Completions Showing Percentage Within Target




SCREENING CYCLE DECISIONS




New Drug Submission (NDS) Screening Decisions

NDS: Screening Cycle Completions Showing Percentage Within Target




SCREENING CYCLE DECISIONS



Supplemental New Drug Submission (SNDS) Screening Decisions





REQUESTS FOR RECONSIDERATION OF FINAL DECISIONS


Requests for Reconsideration of Final Decisions –NDS, SNDS & ANDS

Reconsideration of Final Decisions Requests Received - NDS, SNDS & ANDS									
Fiscal Year of Request (April 1 - March 31)									
Breakdown by Reconsideration Decision 14-15 15-16 16-17 17-18 18-19 Final Decision in Dispute (as of May 2019)							Submission Status (as of May 2019)		
Total Received	0	0	0	0	0				


This page is left blank intentionally.

PRIORITY REVIEW STATUS REQUEST (for NDS & SNDS)


Priority Review Status Requests Received



Priority Review Status Requests: Decisions Rendered



PRIORITY REVIEW STATUS REQUEST (for NDS & SNDS)



Priority Review Status Requests: Performance


REQUESTS FOR RECONSIDERATION OF FINAL DECISIONS

Requests for Reconsideration of Final Decisions – Priority Review Requests (for NDS and SNDS)

"Priority Review Request" - Requests for Reconsideration of Final Decisions									
	Fiscal Year of Request (April 1 - March 31)								
							Submission Status (as of May 2019)		
Total Received	0	0	1	0	1				
Total Granted	0	0	0	0	0				
Total Pending	0	0	0	0	1	PR-SNDS: Priority Review Request Denied	Rejected		
Total Denied	0	0	1	0		PR-SNDS: Priority Review Request Denied	Rejected		


NOTIFIABLE CHANGES (NC)

NOTIFIABLE CHANGES




Number Received - Notifiable Changes (NC)

WORKLOAD



Notifiable Change (NC) SAFETY: Review Workload / Backlog

Notifiable Change (NC) QUALITY: Review Workload / Backlog



WORKLOAD

BGTD NC- SAFETY: REVIEW WORKLOAD AT FISCAL YEAR END									
CLASS 2015-03-31 2016-03-31 2017-03-31 2018-03-31 2019-03-3									
SAFETY - 90 day	22	20	15	8	34				
Backlog	0	0	0	0	0				
SAFETY - 120 day	3	3	4	1	0				
Backlog	0	0	0	0	0				
Total	25	23	19	9	34				
Non Backlog	25	23	19	9	34				
BACKLOG	0	0	0	0	0				
% in Backlog	0%	0%	0%	0%	0%				


Notifiable Change (NC) SAFETY: Review Workload by Class

Notifiable Change (NC) QUALITY: Review Workload by Class


BGTD NC- QUALITY: REVIEW WORKLOAD AT FISCAL YEAR END									
CLASS 2015-03-31 2016-03-31 2017-03-31 2018-03-31 2019-03-31									
QUALITY - 90 day	93	60	59	72	66				
Backlog	4	0	0	3	0				
Total	93	60	59	72	66				
Non Backlog	89	60	59	69	66				
BACKLOG	4	0	0	3	0				
% in Backlog	4%	0%	0%	4%	0%				

PERFORMANCE

REVIEW Completions by Class - Notifiable Changes (NC)



SCREENING Completions by Class - Notifiable Changes (NC)



NC - QUALITY (90)					
DOCUMENT TYPE	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019
NO OBJECTION LETTER	302	410	363	381	358
NOT SATISFACTORY NOTICE	0	3	1	0	0
REJECTION LETTER (SCR)	8	33	7	12	16
CANCELLED BY COMPANY	3	6	13	8	16
SCREENING DEFICIENCY NOTICE	12	7	5	2	0
NC - HOLD (PATENT)	0	0	0	0	3
	•				
NC - SAFETY (90)					
DOCUMENT TYPE	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019
NO OBJECTION LETTER	112	81	97	88	78
NOT SATISFACTORY NOTICE	0	2	0	0	0
REJECTION LETTER (SCR)	5	1	0	0	0
CANCELLED BY COMPANY	4	4	3	6	5
SCREENING DEFICIENCY NOTICE	1	1	1	1	0
NC - HOLD (PATENT)	0	1	0	0	0
NC - SAFETY (120)					

Decision Documents by Class - Notifiable Change (NC)

NC - SAFETY (120)					
DOCUMENT TYPE	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019
NO OBJECTION LETTER	12	15	12	12	6
NOT SATISFACTORY NOTICE	0	2	1	0	0
SCREENING DEFICIENCY NOTICE	0	0	0	1	0
CANCELLED BY COMPANY	1	1	1	2	2

NC - ADMINISTRATIVE					
DOCUMENT TYPE	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019
NO OBJECTION LETTER	43	30	22	9	5

REQUESTS FOR RECONSIDERATION OF FINAL DECISIONS

Requests for Reconsideration of Final Decisions – Notifiable Changes (NC)

NC							
Year of Reconsideration Request							
	14-15	15-16	16-17	17-18	18-19		
Total	0	0	0	0	0		


Administrative Submissions

Submissions in support of a manufacturer or product name change.


ADMINISTRATIVE SUBMISSIONS (BGTD)

(e.g. product name changes that require a drug name review)

Administrative Submissions Received (with BGTD review)




Administrative Submission Approvals (with BGTD Review)




ADMINISTRATIVE SUBMISSIONS

(Manufacturer and/or Product Name Changes)¹³

Administrative Submissions Received by Submission Type



Administrative Submission Approvals (OSIP) for NDS, SNDS, ANDS and SANDS



¹³ The screening functions for Administrative submissions and the review functions for Labelling Only submissions with an Administrative component were moved from the Office of Submissions and Intellectual Property (OSIP) to the labelling area of the Bureau of Gastroenterology, Infection and Viral Diseases (BGIVD) at TPD in December 2018.

Clinical Trial Applications and Amendments

(CTA & CTA-A)

CLINICAL TRIAL APPLICATIONS


CTAs Received by Class (30 day target) Total Total Total 51 Total Total 30 10 No. of CTA -6 2015/2016 2014/2015 2016/2017 2017/2018 2018/2019 Phase 1 HEALTHY HUMAN-30 Phase 1 OTHER - 30 DAYS Phase 1/2 - 30 DAYS Phase 2 - 30 DAYS PHASE 2/3 - 30 DAYS Phase 3 - 30 DAYS Phase Other Total

Number Received - Clinical Trial Application (CTA)

Decision Documents - Clinical Trial Application (CTA)

CTA (30 day target)					
DOCUMENT TYPE	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019
NO OBJECTION LETTER	283	336	328	307	380
CANCELLED BY COMPANY DURING REVIEW	18	10	21	12	7
CANCELLED BY COMPANY AT PROCESSING	5	2	10	6	6
NOT SATISFACTORY NOTICE	4	3	0	0	1
REJECTION LETTER (SCR)	1	1	1	0	2
SCREENING DEFICIENCY NOTICE	0	3	0	0	0

Performance - Clinical Trials Applications (CTA) Reviews Meeting the 30 Day Target



CLINICAL TRIAL APPLICATION-AMENDMENTS


CTA-As Received by Class (30 day target) Total Total Total Total 90 No. of CTA-As Total 37 2014/2015 2015/2016 2016/2017 2017/2018 2018/2019 Phase 1 HEALTHY HUMAN-30 Phase 1 OTHER - 30 DAYS Phase 1/2 - 30 DAYS Phase 2 - 30 DAYS Phase 2/3 - 30 DAYS 🖬 Phase 3 - 30 DAYS Phase Other Total

Number Received - Clinical Trial Application-Amendments (CTA-A)

Decision Documents - Clinical Trial Application-Amendments (CTA-A)

CTA-A (30 day target)					
DOCUMENT TYPE	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019
NO OBJECTION LETTER	574	747	794	869	1048
CANCELLED BY COMPANY DURING REVIEW	8	5	7	15	4
CANCELLED BY COMPANY AT PROCESSING	6	2	10	9	9
NOT SATISFACTORY NOTICE	0	2	0	0	0
REJECTION LETTER (SCR)	5	10	15	15	20

Performance - Clinical Trial Application Amendments (CTA-A) Reviews




Application for a Drug Identification Number


DINB

Biological Products

DINB: Application for a Drug Identification Number – BIOLOGICAL Products



DINB: Number Received




REVIEW WORKLOAD

DINB: Review Workload by Class

DINB All REVIEW WORKLOAD BY FEE CATEGORY - BGTD (excluding administrative) and Fiscal Year End										
	2015-03-31 2016-03-31 2017-03-31 2018-03-31 2019-03-31									
Labelling Only	0	0	6	1	0					
Backlog	0	0	0	0	0					
Chemistry & Manufacturing	5	1	1	0	1					
Backlog	0	0	0	0	0					
Total	5	1	7	1	1					
Non Backlog	5	1	7	1	1					
BACKLOG	0	0	0	0	0					
% in Backlog	0%	0%	0%	0%	0%					

SCREENING WORKLOAD



DINB: Screening Workload Showing Percentage in Backlog

DINB: Screening Workload by Class

DINB All SCREENING WORKLOAD BY FEE CATEGORY - BGTD (excluding dministrative) and Fiscal Year End								
	2015-03-31	2016-03-31	2017-03-31	2018-03-31	2019-03-31			
Labelling Only	0	0	0	0	0			
Backlog	0	0	0	0	0			
Chemistry & Manufacturing	0	0	1	1	0			
Backlog	0	0	0	0	0			
Total	0	0	1	1	0			
Non Backlog	0	0	1	1	0			
BACKLOG	0	0	0	0	0			
% in Backlog	0%	0%	0%	0%	0%			

DECISION DOCUMENTS


DINB - LABELLING ONLY					
DOCUMENT TYPE	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019
NO OBJECTION LETTER	0	0	0	0	0
SCREENING DEFICIENCY NOTICE	0	0	0	0	0
CANCELLED BY COMPANY	0	0	6	6	0
DINB - CHEMISTRY & MANUFACTURING					
DOCUMENT TYPE	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019
NO OBJECTION LETTER	0	0	0	0	0
NOTICE OF DEFICIENCY	0	0	0	0	0
NOTIFICATION FORM DIN SUB	1	0	0	1	0
SCREENING DEFICIENCY NOTICE	6	0	0	1	0
CANCELLED BY COMPANY	0	0	0	0	0
DINB - CLIN/C&M					
DOCUMENT TYPE	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019
NO OBJECTION LETTER	0	0	0	0	0
SCREENING DEFICIENCY NOTICE	2	0	0	0	0
CANCELLED BY COMPANY	0	1	0	0	0
DINB - ADMINISTRATIVE					
DOCUMENT TYPE	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019
NOTIFICATION FORM/DIN ISSUED	2	0	0	0	0
CANCELLED BY COMPANY	0	0	0	1	0
DINB - COMPARATIVE STUDIES					
DOCUMENT TYPE	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019
REJECTION LETTER (SCREENING)	0	1	0	0	0
SCREENING DEFICIENCY NOTICE	0	1	0	0	0

REQUESTS FOR RECONSIDERATION OF FINAL DECISIONS

DINB: Requests for Reconsideration of Final Decisions


DINB							
Year of Reconsideration Request							
	14-15 15-16 16-17 17-18 18-19						
Total	0	0	0	0	0		

PERFORMANCE




DINB: Review Cycle Completions

DINB: Screening Cycle Completions




PDC-B: Post Authorization Division 1 Changes - Biologics



PDC-B: Post Authorization Division 1 Changes- Biologics Received

YBPR: Yearly Biologic Product Reports



Yearly Biologic Product Reports (YBPR) Received

14

¹⁴ Yearly Biologic Product Report (YBPR), is a report that must be submitted annually by manufacturers of all Schedule D (Biologic) drugs. The report contains production information on both drug substance and drug product lots, including test methods and results, reasons for any recalls and corrective action taken, as well as other pertinent post-market information.

Appendix A: Pre-submission Meetings

BGTD: Pre-Meetings Held / Feedback Provided by Submission Type and Fiscal Year 120 100 No. of Submissions 80 60 40 20 0 PRE CLINICAL PRE-NDS PRE-SNDS PRE-NC TRIAL PRE-DIN APPLICATION MEETING MEETING MEETING MEETING MEETING MPNC MPDIN MPNDS MPSNDS PRECTA 2014-15 0 34 24 5 30 2015-16 42 22 2 46 1 2016-17 46 7 40 1 36 2017-18 33 32 4 42 1 2018-19 38 32 0 26 2

Pre-submission Meetings Held / Feedback Provided

15

¹⁵ Prior to filing a submission, the sponsor may request a pre-submission meeting to discuss the presentation of data in support of the submission: For further information, refer to the <u>Guidance for Industry: Management of Drug Submissions</u>

This page is left blank intentionally.